Myostatin x Activin A Bispecific
Obesity and Cardiometabolic Disease
OptimizationActive
Key Facts
About iBio
iBio is focused on creating transformative antibody therapies for obesity and cardiometabolic disorders by integrating artificial intelligence with experimental biology. Its platform enables the discovery of antibodies against challenging targets like GPCRs, with a pipeline featuring candidates designed to preserve muscle mass, target fat selectively, and enable less frequent dosing. The company is advancing multiple programs from discovery through IND-enabling stages, positioning itself in the rapidly expanding obesity therapeutics market.
View full company profileTherapeutic Areas
Other Obesity and Cardiometabolic Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| IBIO-610 | iBio | IND-Enabling |
| IBIO-600 | iBio | IND-Enabling |
| Amylin Antibody | iBio | Optimization |
| Target 4 Program | iBio | Discovery |